It has been previously described that the activation of the PD-1/PD-L1 pathways can lead to an immunosuppressive, anti-apoptotic microenvironment and help the tumor to evade anti-tumor immunity [3,4,5]. The gene discussed is PDCD1; the disease is neoplasm.